Connection

Jeffrey Jones to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Jeffrey Jones has written about Antineoplastic Agents.
Jeffrey Jones
Connection Strength
0.452
Antineoplastic Agents
  1. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75.
    View in: PubMed
    Score: 0.349
  2. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Aug 01; 127(8):3052-3064.
    View in: PubMed
    Score: 0.085
  3. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol. 2015 Nov; 90(11):967-9.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.